10 Barrel Brewing, Widmer Brothers and Hop Valley Named Official Craft Beer Partners of the Portland Trail Blazers

Tilray Brands' three Oregon craft beer subsidiaries—10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing—have been named Official Craft Beer Partners of the Portland Trail Blazers. 10 Barrel also becomes the team's first Official Canned Cocktail Partner. The partnership expands craft beverage offerings at Moda Center through new venues like Schonely's Oregon Beer Hall and extends to the Rip City Bar Network.

11/12/2026, 7:00 AM • GlobeNewswire

Does Marijuana Rescheduling Really Help Tilray's Stock?

The U.S. government's reclassification of medical cannabis from Schedule I to Schedule III primarily benefits U.S.-based cannabis operators through lower tax bills, not Canadian producer Tilray. While rescheduling may be a step toward legalization, it doesn't guarantee future reform and could take years to materialize. Investors should be cautious about overreacting to rescheduling news, as Tilray's stock has historically surged temporarily on cannabis reform announcements only to decline to new lows.

11/10/2026, 6:05 AM • The Motley Fool

Tilray Raises Its Guidance for the Year. Is the Stock Finally Headed on the Right Track?

Tilray announced a consolidation of its Canadian operations expected to generate $10 million in annual cost savings, leading to slightly raised adjusted EBITDA guidance for fiscal 2027 ($70-75 million vs. previous $68-75 million). However, the company continues to burn cash and faces challenges in the competitive Canadian cannabis market with low margins. Analysts remain cautious, suggesting investors take a wait-and-see approach as the improvements are insufficient to make the stock a compelling buy.

11/09/2026, 8:26 AM • The Motley Fool

Which of These 5 Cannabis Stocks Has the Strongest Balance Sheet?

An analysis of five major cannabis stocks reveals significant differences in financial health. Cronos Group leads with approximately $841 million in cash and no significant debt, followed closely by SNDL, which is debt-free with positive free cash flow. Tilray and Canopy Growth continue to struggle with debt and negative cash flow despite some revenue growth, while Aurora Cannabis has a smaller liquidity cushion. A strong balance sheet provides financial flexibility but doesn't guarantee profitability or shareholder returns.

11/08/2026, 5:32 AM • The Motley Fool

Forget U.S. Rescheduling: Tilray's 71% Growth in Europe Is the Story Investors Are Missing

Tilray Brands has successfully transformed from a pure-play marijuana company into a diversified global consumer packaged goods company. In fiscal Q1 2027, beverage sales (largely beer) reached $101.5 million, up 82% year-over-year, now exceeding cannabis revenue of $56.1 million. The company achieved 71% growth in Europe, Middle East, and Africa (EMEA) markets, signaling successful international expansion beyond the U.S. marijuana market. While still unprofitable, Tilray's strategic pivot toward beverages and wellness positions it for potential sustainable profitability.

11/01/2026, 4:15 PM • The Motley Fool

Canopy Growth vs. Tilray Brands: Quarterly Revenue Scale and Consistency in Cannabis

Tilray Brands maintains a 4x revenue advantage over Canopy Growth, consistently generating $200+ million quarterly revenue compared to Canopy's $45-73 million. While both companies show year-over-year growth when comparing comparable quarters, Tilray demonstrates more stable and higher revenue levels. Canopy's latest Q4 2025 quarter ($73.3M) suggests potential momentum, but the revenue gap remains substantial.

10/30/2026, 2:59 PM • The Motley Fool

Down 70% in 2026, Has Tilray's Stock Finally Bottomed Out?

Tilray Brands stock has plummeted 70% in 2026 and 97% over five years despite generating nearly $1 billion in revenue. While the company has grown through acquisitions in beverages and alcohol, it remains unprofitable with an operating loss of $60.5 million over the trailing 12 months. The analyst argues the stock could fall further due to weak organic growth, continued cash burn, and limited profitability prospects, despite its low valuation of $400 million market cap.

10/27/2026, 8:46 AM • The Motley Fool

Tilray Now Sells More Beer Than Cannabis. Here's Why That Might Be Good News for Investors.

Tilray has transformed from a pure cannabis company into a diversified consumer packaged goods company. In Q1 fiscal 2027, alcoholic beverage revenues ($101.5M) surpassed cannabis revenues ($56.1M) following the acquisition of BrewDog. While the company achieved record revenues, improved gross margins, and reached a net cash position, it remains unprofitable, making it a high-risk investment suitable primarily for aggressive growth investors.

10/25/2026, 7:15 AM • The Motley Fool

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?

The article compares two major cannabis companies navigating industry challenges. Canopy Growth focuses on premium Canadian cannabis and European medical sales but faces internal control weaknesses and significant losses. Tilray Brands has diversified into beverages and international markets, posting record Q1 revenue of $257M with improving margins. The author recommends Tilray as the better choice due to its larger scale, diversified revenue streams, and clearer path to profitability, though both stocks remain risky investments in a volatile industry.

10/15/2026, 5:54 PM • The Motley Fool

SweetWater Brewing Gives Fans the Chance to Win Tickets to Their Dream Show at AEG Venues Across Georgia

SweetWater Brewing, a craft brewery brand by Tilray Brands, launched a concert sweepstakes giving fans 21+ the chance to win tickets to 2026-2027 AEG concerts at select Georgia venues including Georgia Theatre, The Eastern, Variety Playhouse, and Terminal West. Two winners will be selected with prizes valued at approximately $1,200 each, including concert tickets and travel gift cards. The sweepstakes runs through December 31, 2026.

10/15/2026, 7:00 AM • GlobeNewswire

3 Huge Red Flags From Tilray's Q1 Earnings Report

Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.

10/12/2026, 2:25 PM • The Motley Fool

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products. Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.

10/10/2026, 5:18 PM • The Motley Fool

Tilray Brands: Is the Stock a Buy at Less Than $4?

Tilray Brands stock has crashed 60% this year and trades below $4, down 84% from its 52-week high. Despite record revenue of $915 million, the company posted a net loss of $105 million and burned $69 million in cash. The analyst recommends avoiding the stock due to poor growth prospects, a highly competitive Canadian market, and a questionable pivot to beverages that doesn't address fundamental business challenges.

10/06/2026, 9:15 AM • The Motley Fool

Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky Stock

Tilray Brands has lost over 50% of its value in 2026 and is down 95% over five years, making it a highly risky investment. However, the bullish case centers on potential U.S. marijuana legalization, which could trigger significant stock appreciation even before full legalization occurs. The company has diversified into beverages and alcohol to position itself for future U.S. market entry. While the stock could surge on legalization discussions similar to Canada's 2018 experience, investors should be aware of substantial risks and uncertainty.

09/15/2026, 10:39 AM • The Motley Fool

Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.

09/05/2026, 7:15 AM • The Motley Fool